Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $358,371.45 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Ventures L.P. 5Am sold 52,317 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $6.85, for a total value of $358,371.45. Following the completion of the sale, the insider owned 2,783,781 shares in the company, valued at $19,068,899.85. This represents a 1.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Entrada Therapeutics Stock Up 8.9%

TRDA stock opened at $7.67 on Thursday. Entrada Therapeutics, Inc. has a 52 week low of $5.02 and a 52 week high of $16.45. The firm has a market capitalization of $298.67 million, a P/E ratio of -1.94 and a beta of -0.26. The company has a fifty day simple moving average of $6.89 and a two-hundred day simple moving average of $9.62.

Entrada Therapeutics (NASDAQ:TRDA) last announced its earnings results on Wednesday, August 5th. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%.The company had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $2.32 million. As a group, analysts anticipate that Entrada Therapeutics, Inc. will post -4.04 EPS for the current year.

Key Headlines Impacting Entrada Therapeutics

Here are the key news stories impacting Entrada Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $4.19 from $4.33 and its FY2027 estimate to a loss of $3.13 from $3.14. The improved longer-term forecasts may be helping sentiment, although the firm maintained a Neutral rating.
• Neutral Sentiment: HC Wainwright slightly worsened its estimates for the third and fourth quarters of 2026, forecasting losses of $1.18 and $1.04 per share, respectively. The revisions suggest continued heavy spending and ongoing losses, with the firm’s full-year FY2026 estimate still below the current consensus loss estimate of $4.07 per share.
• Neutral Sentiment: Institutional ownership remains high at approximately 86.4%. BlackRock established a new position, while Millennium Management, Citadel Advisors and Qube Research increased their holdings. These institutional purchases may provide some support, although the reported transaction periods are inconsistent and should be interpreted cautiously.
• Negative Sentiment: Major shareholder Ventures V. L.P. 5Am sold 62,811 shares for approximately $431,829 across August 6 and 7. Director Kush Parmar also sold 155,255 shares for roughly $1.08 million from August 6 through 10. The sales reduced their respective holdings but did not represent complete exits, as both continued to own substantial positions. SEC insider transaction filings
• Negative Sentiment: Entrada’s latest quarterly results were weaker than expected: the company reported a $1.01-per-share loss versus the $0.97 consensus estimate and revenue of $0.90 million versus expectations of $2.32 million. As a clinical-stage biotechnology company, TRDA remains dependent on pipeline progress and future financing rather than current operating profits.

Analyst Ratings Changes

A number of analysts recently issued reports on TRDA shares. Weiss Ratings lowered Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, June 11th. Roth Capital restated a “buy” rating and set a $11.00 price objective on shares of Entrada Therapeutics in a report on Wednesday. HC Wainwright lowered Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. Finally, Guggenheim dropped their price target on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Monday, June 8th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $17.75.

Institutional Investors Weigh In On Entrada Therapeutics

Several large investors have recently modified their holdings of the business. State of Wyoming bought a new position in shares of Entrada Therapeutics during the second quarter valued at approximately $37,000. Russell Investments Group Ltd. raised its stake in Entrada Therapeutics by 72.7% in the third quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock worth $51,000 after buying an additional 3,707 shares in the last quarter. Occudo Quantitative Strategies LP bought a new position in Entrada Therapeutics in the second quarter worth approximately $68,000. Jain Global LLC purchased a new stake in Entrada Therapeutics during the third quarter worth $69,000. Finally, IHT Wealth Management LLC purchased a new stake in Entrada Therapeutics during the second quarter worth $72,000. Institutional investors own 86.39% of the company’s stock.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.